DES MOINES, Iowa, Jan. 24, 2018 /PRNewswire/ — Eurofins Food Safety Systems was recognized as an independent certification body by BRC Global Standards on January 11. Eurofins US Food Safety Systems division is now able to conduct audits for BRC Global Standard for Food Safety Issue 7 and BRC Global Standard for Storage and Distribution Issue 3.

Eurofins Scientific (PRNewsFoto/Eurofins Scientific)

«We are very excited to add the BRC Global Standards for Food Safety as well as Storage and Distribution to our scope of certification services in North America,» said Gary Smith, Director of Eurofins Food Safety Systems. «We have been executing this program working with our regional partners over the last two years and we are ready to bring the process in-house.»

Eurofins Food Safety Systems began the BRC certification body application process in early December 2017. Executing the BRC certification program in house will allow Eurofins to service customers faster and respond to the growth expected within the BRC program over the next few years. Prior to this certification, certificates were issued by Eurofins’ European auditing group.

«This will allow for a much more efficient and improved customer service experience. Managing the certification locally will also allow us to expand our regional partnerships,» said Kris Middleton, Technical Manager at Eurofins Food Safety Systems.

Maintaining this program will enable Eurofins to easily adapt when BRC Global Standards for Food Safety Issue 8 is published. Becoming a certification body allows Eurofins North American auditing group to act as a direct connection between customers and BRC Global Standards.

«Eurofins is excited to increase their offerings and believes providing this program shows our commitment to growing the US and North American brand,» said Middleton.

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes «Eurofins» or «the Group») believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 42 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.


Cision View original content with multimedia:

SOURCE Eurofins